keyword
MENU ▼
Read by QxMD icon Read
search

Blood test for lung cancer

keyword
https://www.readbyqxmd.com/read/29785657/novel-non-invasive-early-detection-of-lung-cancer-using-liquid-immunobiopsy-metabolic-activity-profiles
#1
Yochai Adir, Shoval Tirman, Shirley Abramovitch, Cynthia Botbol, Aviv Lutaty, Tali Scheinmann, Eyal Davidovits, Irit Arbel, Giora Davidovits, Sonia Schneer, Michal Shteinberg, Hagit Peretz Soroka, Ruven Tirosh, Fernando Patolsky
Lung cancer is the leading cause of cancer death worldwide. Survival is largely dependent on the stage of diagnosis: the localized disease has a 5-year survival greater than 55%, whereas, for spread tumors, this rate is only 4%. Therefore, the early detection of lung cancer is key for improving prognosis. In this study, we present an innovative, non-invasive, cancer detection approach based on measurements of the metabolic activity profiles of immune system cells. For each Liquid ImmunoBiopsy test, a 384 multi-well plate is loaded with freshly separated PBMCs, and each well contains 1 of the 16 selected stimulants in several increasing concentrations...
May 21, 2018: Cancer Immunology, Immunotherapy: CII
https://www.readbyqxmd.com/read/29776385/generation-of-ventilation-perfusion-ratio-map-in-surgical-patients-by-dual-energy-ct-after-xenon-inhalation-and-intravenous-contrast-media
#2
Kohei Aoki, Yotaro Izumi, Wataru Watanabe, Yuji Shimizu, Hisato Osada, Norinari Honda, Toshihide Itoh, Mitsuo Nakayama
BACKGROUND: While many studies have evaluated the change in lung volume before and after lung resection and correlated this with pulmonary function test results, there is very little evidence on the changes in ventilation perfusion ratio (V/Q) before versus after lung resection. In the present pilot study, we evaluated if V/Q mapping can be constructed using dual energy CT images. METHODS: Thirty-one lung cancer patients planned for pulmonary resection were included in this study...
May 18, 2018: Journal of Cardiothoracic Surgery
https://www.readbyqxmd.com/read/29758930/the-potential-predictive-value-of-circulating-immune-cell-ratio-and-tumor-marker-in-atezolizumab-treated-advanced-non-small-cell-lung-cancer-patients
#3
Minglei Zhuo, Hanxiao Chen, Tianzhuo Zhang, Xue Yang, Jia Zhong, Yuyan Wang, Tongtong An, Meina Wu, Ziping Wang, Jing Huang, Jun Zhao
BACKGROUND: The PD-L1 antibody atezolizumab has shown promising efficacy in patients with advanced non-small cell lung cancer. But the predictive marker of clinical benefit has not been identified. OBJECTIVE: This study aimed to search for potential predictive factors in circulating blood of patients receiving atezolizumab. METHODS: Ten patients diagnosed with advanced non-small cell lung cancer were enrolled in this open-label observing study...
May 4, 2018: Cancer Biomarkers: Section A of Disease Markers
https://www.readbyqxmd.com/read/29758197/berberine-and-zinc-oxide-based-nanoparticles-for-the-chemo-photothermal-therapy-of-lung-adenocarcinoma
#4
Sungyun Kim, Song Yi Lee, Hyun-Jong Cho
Organic/inorganic hydrid nanoparticles (NPs) composed of berberine (BER) and zinc oxide (ZnO) were developed for the therapy of lung cancers. Without the use of pharmaceutical excipients, NPs were fabricated with only dual anticancer agents (BER and ZnO) by facile blending method. The mean weight ratio between BER and ZnO in BER-ZnO NPs was 39:61 in this study. BER-ZnO NPs dispersed in water exhibited 200-300 nm hydrodynamic size under 5 mg/mL concentration. The exposure of both BER and ZnO in the outer layers of BER-ZnO NPs was identified by X-ray photoelectron spectroscopy analysis...
May 11, 2018: Biochemical and Biophysical Research Communications
https://www.readbyqxmd.com/read/29748012/a-phase-i-study-of-nintedanib-combined-with-cisplatin-gemcitabine-as-first-line-therapy-for-advanced-squamous-non-small-cell-lung-cancer-lume-lung-3
#5
Martin Forster, Allan Hackshaw, Tommaso De Pas, Manuel Cobo, Pilar Garrido, Yvonne Summers, Anne-Marie C Dingemans, Michael Flynn, David Schnell, Ute von Wangenheim, Arsene-Bienvenu Loembé, Rolf Kaiser, Siow Ming Lee
BACKGROUND: There are limited treatment options for squamous non-small cell lung cancer (sqNSCLC) and prognosis remains poor. The safety and pharmacokinetics (PK) of nintedanib, a triple angiokinase inhibitor, plus cisplatin/gemcitabine as first-line treatment for advanced sqNSCLC patients, were evaluated. MATERIALS AND METHODS: A phase I, dose-escalation study administering drugs in a 21-day cycle: cisplatin (75 mg/m2 , Day 1), gemcitabine (1250 mg/m2 , Days 1 and 8) and nintedanib (Days 2-7, 9-21) were given for 4-6 cycles, followed by monotherapy until disease progression or adverse events (AEs)...
June 2018: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/29731983/exosomal-mirnas-species-in-the-blood-of-small-cell-and-non-small-cell-lung-cancer-patients
#6
Valeriy Poroyko, Tamara Mirzapoiazova, Arin Nam, Isa Mambetsariev, Bolot Mambetsariev, Xiwei Wu, Aliya Husain, Everett E Vokes, Deric L Wheeler, Ravi Salgia
Lung cancer is a devastating disease with overall bleak prognosis. Current methods to diagnose lung cancer are rather invasive and are inadequate to detect the disease at an early stage when treatment is likely to be most effective. In this study, a shotgun sequencing approach was used to study the microRNA (miRNA) cargo of serum-derived exosomes of small cell lung cancer (SCLC) (n=9) and non-small cell lung cancer (NSCLC) (n=11) patients, and healthy controls (n=10). The study has identified 17 miRNA species that are differentially expressed in cancer patients and control subjects...
April 13, 2018: Oncotarget
https://www.readbyqxmd.com/read/29729229/triple-test-with-tumor-markers-cyfra-21-1-he4-and-progrp-might-contribute-to-diagnosis-and-subtyping-of-lung-cancer
#7
Elif Tugce Korkmaz, Deniz Koksal, Funda Aksu, Z Gunnur Dikmen, Duygu Icen, Emin Maden, Sevgen Onder, Filiz Akbiyik, Salih Emri
BACKGROUND AND AIM: Early diagnosis and histological subtyping are important issues in the management of patients with lung cancer (LC). The aim of this study is to investigate the diagnostic value of a panel of serum tumor markers in newly diagnosed patients with LC. METHODS: Venous blood samples were collected from 99 patients with LC (42 adenocarcinoma, 35 squamous, and 22 small cell carcinoma) and 30 patients with benign lung disease. Progastrin releasing peptide (ProGRP), squamous cell carcinoma antigen (SCCAg), cytokeratin 19-fragments (CYFRA 21...
May 2, 2018: Clinical Biochemistry
https://www.readbyqxmd.com/read/29719623/validation-and-comparison-of-two-ngs-assays-for-the-detection-of-egfr-t790m-resistance-mutation-in-liquid-biopsies-of-nsclc-patients
#8
Claudia Vollbrecht, Annika Lehmann, Dido Lenze, Michael Hummel
Analysis of circulating cell-free DNA (cfDNA) derived from peripheral blood ("liquid biopsy") is an attractive alternative to identify non-small cell lung cancer (NSCLC) patients with the EGFR T790M mutation eligible for 3rd generation tyrosine kinase inhibitor therapy. We evaluated two PCR-based next generation sequencing (NGS) approaches, one including unique molecular identifiers (UMI), with focus on highly sensitive EGFR T790M mutation detection. Therefore, we extracted and sequenced cfDNA from synthetic plasma samples spiked with mutated DNA at decreasing allele frequencies and from 21 diagnostic NSCLC patients...
April 6, 2018: Oncotarget
https://www.readbyqxmd.com/read/29707129/circulating-programmed-death-ligand-1-cpd-l1-in-non-small-cell-lung-cancer-nsclc
#9
Silvia Vecchiarelli, Francesco Passiglia, Armida D'Incecco, Marianna Gallo, Antonella De Luca, Elisa Rossi, Federica D'Incà, Gabriele Minuti, Lorenza Landi, Chiara Bennati, Michela Spreafico, Manolo D'Arcangelo, Valentina Mazza, Nicola Normanno, Federico Cappuzzo
Background: This study aimed at investigating feasibility of programmed death ligand-1 (PD-L1) testing in plasma samples of advanced NSCLC patients receiving first-line treatment, assessing whether circulating (c)PD-L1 levels were modified by the therapy and whether baseline cPD-L1 levels were associated with patients' clinical responses and survival outcome. Methods: Peripheral blood samples were collected from 16 healthy volunteers and 56 newly diagnosed NSCLC patients before and at 12th week during the course of first-line therapy...
April 3, 2018: Oncotarget
https://www.readbyqxmd.com/read/29684106/urine-antigen-detection-as-an-aid-to-diagnose-invasive-aspergillosis
#10
Kieren A Marr, Kausik Datta, Seema Mehta, Darin B Ostrander, Michelle Rock, Jesse Francis, Marta Feldmesser
Background: Establishing rapid diagnoses of invasive aspergillosis (IA) is priority, given poor outcomes of late therapy. Non-culture based tests that detect galactomannan and β-D glucan are available, but are technically cumbersome and rely on invasive sampling (blood or bronchoalveolar lavage). Methods: We optimized a lateral flow dipstick assay using the galactofuranose -specific monoclonal antibody (mAb476), which was previously shown to recognize urine antigens after Aspergillus fumigatus pulmonary infection in an`imals...
April 19, 2018: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
https://www.readbyqxmd.com/read/29682444/molecular-detection-of-emt-markers-in-circulating-tumor-cells-from-metastatic-non-small-cell-lung-cancer-patients-potential-role-in-clinical-practice
#11
Annalisa Milano, Francesca Mazzetta, Sabatino Valente, Danilo Ranieri, Laura Leone, Andrea Botticelli, Concetta Elisa Onesti, Salvatore Lauro, Salvatore Raffa, Maria Rosaria Torrisi, Paolo Marchetti
Background: Non-small cell lung cancer (NSCLC) is the most common cause of cancer-related mortality; nevertheless, there are few data regarding detection of circulating tumor cells (CTCs) in NSCLC, compared to other kinds of cancers in which their prognostic roles have already been defined. This difference is likely due to detection methods based on the epithelial marker expression which ignore CTCs undergoing epithelial-mesenchymal transition (CTCsEMT ). Methods: After optimization of the test with spiking experiments of A549 cells undergoing TGF- β 1-induced EMT (A549EMT ), the CTCsEMT were enriched by immunomagnetic depletion of leukocytes and then characterized by a RT-PCR assay based on the retrieval of epithelial and EMT-related genes...
2018: Analytical Cellular Pathology (Amsterdam)
https://www.readbyqxmd.com/read/29656751/circulating-tumor-dna-testing-in-advanced-non-small-cell-lung-cancer
#12
REVIEW
Everett J Moding, Maximilian Diehn, Heather A Wakelee
Circulating tumor DNA (ctDNA) shed from cancer cells into the peripheral blood can be non-invasively collected and tested for the presence of tumor-specific mutations. Mutations identified in ctDNA can predict responses to targeted therapies and emerging evidence suggests that changes in ctDNA levels over time can be used to monitor response to therapy and detect disease recurrence. Given the emergence of targeted therapies in advanced non-small cell lung cancer (NSCLC), liquid biopsies utilizing ctDNA testing represent a powerful approach to genotype tumors and monitor for the development of resistance...
May 2018: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/29652817/selenium-in-radiation-oncology-15-years-of-experiences-in-germany
#13
REVIEW
Ralph Muecke, Oliver Micke, Lutz Schomburg, Jens Buentzel, Klaus Kisters, Irenaeus A Adamietz
Introduction: Se measurement and supplementation in radiation oncology is a controversial issue. The German Working Group Trace Elements and Electrolytes in Oncology (AKTE) has conducted a number of studies on this issue, which are summarized in this review. Strategies have been tested and developed, aiming to stratify the patients with a potential need for supplemental Se and how best to monitor Se supplementation with respect to health effects and risks. Methods: We analyzed blood and tissue Se-levels of different tumor patients ( n = 512)...
April 13, 2018: Nutrients
https://www.readbyqxmd.com/read/29625385/targeting-macrophage-immunometabolism-dawn-in-the-darkness-of-sepsis
#14
REVIEW
V Kumar
Sepsis is known since the time (470 BC) of great Greek physician, Hippocrates. Advancement in modern medicine and establishment of separate branches of medical science dealing with sepsis research have improved its outcome. However, mortality associated with sepsis still remains higher (25-30%) that further increases to 40-50% in the presence of septic shock. For example, sepsis-associated deaths account more in comparison to deaths-associated with myocardial-infarction and certain cancers (i.e. breast and colorectal cancer)...
May 2018: International Immunopharmacology
https://www.readbyqxmd.com/read/29623586/comparison-of-plasma-ctdna-and-tissue-cytology-based-techniques-for-the-detection-of-egfr-mutation-status-in-advanced-nsclc-spanish-data-subset-from-assess
#15
E Arriola, A Paredes-Lario, R García-Gomez, P Diz-Tain, M Constenla, C García-Girón, G Márquez, M Reck, G López-Vivanco
PURPOSE: The analysis of epidermal growth factor receptor (EGFR) mutations in many patients with advanced non-small-cell lung cancer (aNSCLC) has provided the opportunity for successful treatment with specific, targeted EGFR tyrosine kinase inhibitors. However, this therapeutic decision may be challenging when insufficient tumor tissue is available for EGFR mutation testing. Therefore, blood surrogate samples for EGFR mutation analysis have been suggested. METHODS: Data were collected from the Spanish cohort of patients in the large, non-interventional, diagnostic ASSESS study (NCT01785888) evaluating the utility of circulating free tumor-derived DNA from plasma for EGFR mutation testing...
April 5, 2018: Clinical & Translational Oncology
https://www.readbyqxmd.com/read/29621357/oncolytic-effect-of-wild-type-newcastle-disease-virus-isolates-in-cancer-cell-lines-in-vitro-and-in-vivo-on-xenograft-model
#16
Kseniya S Yurchenko, Peipei Zhou, Anna V Kovner, Evgenii L Zavjalov, Lidiya V Shestopalova, Alexander M Shestopalov
Oncolyic virotherapy is one of the modern experimental techniques to treat human cancers. Here we studied the antitumor activity of wild-type Newcastle disease virus (NDV) isolates from Russian migratory birds. We showed that NDV could selectively kill malignant cells without affecting healthy cells. We evaluated the oncolytic effect of 44 NDV isolates in 4 histogenetically different human cell lines (HCT116, HeLa, A549, MCF7). The safety of the isolates was also tested in normal peripheral blood mononuclear (PBMC) cells...
2018: PloS One
https://www.readbyqxmd.com/read/29600060/positive-correlation-between-postoperative-tumor-recurrence-and-changes-in-circulating-tumor-cell-counts-in-pulmonary-venous-blood-pvctc-during-surgical-manipulation-in-non-small-cell-lung-cancer
#17
Masaki Hashimoto, Fumihiro Tanaka, Kazue Yoneda, Teruhisa Takuwa, Seiji Matsumoto, Yoshitomo Okumura, Nobuyuki Kondo, Tohru Tsujimura, Takashi Nakano, Seiki Hasegawa
Background: In non-small cell lung cancer (NSCLC), circulating tumor cells (CTC) are shed and circulate to the peripheral blood through the pulmonary vein. Previously, CTC count in pulmonary venous blood (pvCTC) was shown to significantly increase after surgical manipulation. Therefore, we assessed the correlation between the changes in the pvCTC count (ΔpvCTC) and clinical outcomes. Methods: Consecutive patients with peripheral-type, NSCLC, who underwent lobectomy or bi-lobectomy through open thoracotomy, were enrolled prospectively...
January 2018: Journal of Thoracic Disease
https://www.readbyqxmd.com/read/29599906/dynamic-changes-during-the-treatment-of-pancreatic-cancer
#18
Robert A Wolff, Andrea Wang-Gillam, Hector Alvarez, Hervé Tiriac, Dannielle Engle, Shurong Hou, Abigail F Groff, Anthony San Lucas, Vincent Bernard, Kelvin Allenson, Jonathan Castillo, Dong Kim, Feven Mulu, Jonathan Huang, Bret Stephens, Ignacio I Wistuba, Matthew Katz, Gauri Varadhachary, YoungKyu Park, James Hicks, Arul Chinnaiyan, Louis Scampavia, Timothy Spicer, Chiara Gerhardinger, Anirban Maitra, David Tuveson, John Rinn, Gregory Lizee, Cassian Yee, Arnold J Levine
This manuscript follows a single patient with pancreatic adenocarcinoma for a five year period, detailing the clinical record, pathology, the dynamic evolution of molecular and cellular alterations as well as the responses to treatments with chemotherapies, targeted therapies and immunotherapies. DNA and RNA samples from biopsies and blood identified a dynamic set of changes in allelic imbalances and copy number variations in response to therapies. Organoid cultures established from biopsies over time were employed for extensive drug testing to determine if this approach was feasible for treatments...
March 13, 2018: Oncotarget
https://www.readbyqxmd.com/read/29564940/quantitative-measurement-of-oxidative-damage-in-erythrocytes-as-indicator-in-benzene-intoxications
#19
José Luis Martínez-Rodríguez, Rosalinda Gutiérrez-Hernández, Claudia Araceli Reyes-Estrada, Angelica Judith Granados-López, Tatiana Arcos-Ortega, Jesús Adrián López
The metabolism of aromatic hydrocarbons by the organism forms products that cause cell death depending on the type of exposure. Benzene exposure has been linked to oxidative stress, hepatic damage, aplastic anemia and hematopoietic cancer as lymphoid and myeloid leukemia. However, there are not fast methods to evaluate chronically benzene exposure in human blood. The objective of this work was the evaluation of the correlation between oxidative damage with benzene exposure and the level of Cellular Plasma Membrane Stability (CPMS) in erythrocytes to use it as a future indicator to determine the grade of benzene intoxications...
March 22, 2018: Toxicology Mechanisms and Methods
https://www.readbyqxmd.com/read/29559795/reliability-of-using-circulating-tumor-cells-for-detecting-epidermal-growth-factor-receptor-mutation-status-in-advanced-non-small-cell-lung-cancer-patients-a-meta-analysis-and-systematic-review
#20
Fang Hu, Xiaowei Mao, Yujun Zhang, Xiaoxuan Zheng, Ping Gu, Huimin Wang, Xueyan Zhang
Purpose: To evaluate the clinical value of circulating tumor cells as a surrogate to detect epidermal growth factor receptor mutation in advanced non-small-cell lung cancer (NSCLC) patients. Methods: We searched the electronic databases, and all articles meeting predetermined selection criteria were included in this study. The pooled sensitivity, specificity, positive likelihood ratio, negative likelihood ratio, and diagnostic odds ratio were calculated. The evaluation indexes of the diagnostic performance were the summary receiver operating characteristic curve and area under the summary receiver operating characteristic curve...
2018: OncoTargets and Therapy
keyword
keyword
24482
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"